RxDoctor Payments Data

Jonathan Mowrey, MD

Nephrology · Independence, MONPI 1659878874

Payments from drug & device makers

$691in general payments, 2019–2025

Across 24 payments — averaging $28.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$125
  • Takeda Pharmaceuticals U.S.A., Inc.$124
  • Mozarc Medical US LLC$104
  • Novo Nordisk$74
  • Otsuka America Pharmaceutical, Inc.$72
  • Amgen$46
  • plus $146 from 7 others

What the payments were for

  • Food & beverage$691100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$691 in reported general payments places this provider in the 45th percentile of 253 nephrology providers in Missouri.

See all nephrology providers in Missouri

Medicare billing

Part B allowed, 2024
$205,037
Medicare patients
562
Services billed
1,886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin106$106,590
FarxigaDapagliflozin Propanediol71$77,011
OzempicSemaglutide37$57,716
FosrenolLanthanum Carbonate11$25,262
Sevelamer Carbonate52$10,176
VeltassaPatiromer Calcium Sorbitex11$7,340
Torsemide174$4,598
MyrbetriqMirabegron12$3,930
Tamsulosin Hcl173$2,403
Losartan Potassium190$2,298
Carvedilol108$1,351
Telmisartan46$1,132
Calcitriol54$1,123
Potassium Citrate ErPotassium Citrate15$840
Amlodipine Besylate138$801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$34$106,590106 claims
AstraZenecaFarxiga$125$77,01171 claims
Novo NordiskOzempic$74$57,71637 claims
Takeda Pharmaceuticals U.S.A., Inc.Fosrenol$124$25,26211 claims
ANI Pharmaceuticals, Inc.Valsartan$27$20119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 253 nephrology providers in Missouri.

Other nephrology in Independence

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →